1Lonneux M, Borbath Ⅱ , Berliere M, et al. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer [J]. Clin Positron Imaging, 2000,3:45.
2Ohta M,Tokuda Y,Suzuki Y,et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99TCm-MDP bone scintigraphy [J]. Nucl Med Commun, 2001,22: 875.
3Yang SN,Liang JA,Lin FJ,et al. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer[J]. J Cancer Res Clin Oncol, 2002,128: 325.
4Moon DH, Maddahi J, Silverman DH, et al. Accuracy of whole-body fluorine-18-FDG PET for detection of recurrent or metastatic breast carcinoma[J]. J Nucl Med, 1998,39:431.
5Gallowitsch HJ,Kresnik E,Gasser J,et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the followw-up of patients with breast carcinoma: a comparison to conventional imaging[J]. Invest Radiol, 2003,38: 250.
6Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer[J]. J Clin Oncol, 2001,19: 2797.
7Yeh SD,Imbriaco M,Larson SM,et al. Detection of bone metastases of androgen-independent prostate cancer by PET-FDG[J]. Nucl Med Biol, 1996,23: 693.
9Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small Cell lung Cancer with whole body PET[J]. Radiology, 1999,212:803.
10Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer[J]. Eur J Nucl Med, 1998,25:1244.
6[2]Schirrmeister H,Arslandemir C,Glatting G,et al.Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer[J].Eur J Nucl Med Mol Imaging,2004,31(3):964-968.
7[3]Hetzel M,Hetzel J,Arslandemir C,et al.Reliability of symptoms to determine Uge of bone scans to identify bone metastases in lung cancer:.prospective study[J].BMJ,2004,328(7447):1051-1052.
8[4]National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology V.2.2008 Non-smaH cell Lung Cancer[EB/OL]http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
9[5]Scher HI,Yagoda A.Bone metastases:pathogenesis,treatment,and rationale for USe of resorption inhibitors[J].Am J Med,1987,82(2A):6-28.
10[6]Salmon JM,Kilpatrick SE.Pathology of skeletal metastases[J].Orthop Clin North Am,20003 1(4):537-544.
